Famotidine
Famotidine. H2 receptor antagonist — suppresses gastric acid via H2 → cAMP → parietal cell. Renally cleared; no CYP metabolism → essentially no… Oral half-life 3.6 h.
H2 receptor antagonist — suppresses gastric acid via H2 → cAMP → parietal cell. Renally cleared; no CYP metabolism → essentially no DDI footprint (preferred over cimetidine for this reason).
PK: this record PASSES the two-arm check — its citation genuinely administered both oral and intravenous doses to the same six volunteers — and its volume is IV-derived at 1.13 L/kg, so pairing it with an independent bioavailability is CORRECT and was checked before judging. Two defects remain. The intravenous half-life of 3.6 h is the ORAL value copied across: the same paper states "an initial half-life (t1/2) of 0.5 h and a terminal t1/2 of 4.0 h" for the intravenous arm, and the half-life here is genuinely route-specific. And F 0.45 matches neither the stated "ranged from 20 to 66%" nor its midpoint; the measured figure of 43% is now carried. ka 1 dropped, the registry modal default.
Pharmacokinetics
- Oral — t½ 3.6 h · F 43% · Vd 79 L
- IV — t½ 4 h · F 100% · Vd 79 L
Sources: PMID:2892544